Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1997-01-09
1999-06-01
Tsang, Cecilia J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 3, 514 12, 514 15, 4241301, 4241841, 4242611, A61K 914
Patent
active
059088257
ABSTRACT:
A nasal dosage composition for nasal delivery comprising (A) a therapeutic agent; and (B) zonula occludens toxin, as well as a method for the use of the same.
REFERENCES:
patent: 5470729 (1995-11-01), Kaper et al.
patent: 5665389 (1997-09-01), Fasano
Fasano et al., `Vibrio Chlerae Produces a Second Entertoxin, Which Affects Intestinal Tight Junctions`, vol. 88, pp. 5242-5246, Jun. 1991.
Kaper et al., `CHOLERA`, Clinical Microbiology Reviews, vol. 8, No. 1, pp. 48-61, Jan. 1995.
Werner et al., `Development of Human Nasal Epithelial Cell Culutre Model and its Sutability for Transport and Metabolism Studies Under in vitro Conditions`, Pharmaceutical Research, vol. 12, No. 4pp. 565-571, 1995.
Herard et al., `Epithelial Barrier Integrity During in vitro Sound Repair of the Airway Epithelium`, vol. 15, pp. 624-632, 1996.
Fiore et al, Gastroenterology, 110:A323 (1996).
Fasano et al, The Journal of Clinical Investigations, Inc., 96:710-720 (1995).
Di Tommaso et al, Infection and Immunity, 64(3):974-979 (1996).
Hochman et al, "Mechanism of Absorption Enhancement and Tight Junction Regulation", J. or Controlled Release, 29:253-267 (1994).
Fasano et al, Mechanism of Action of Zonula Occludens Toxin (ZOT) Elaborated by Vibrio cholerae, 29th Joint Conference on Cholera and Related Diarrheal Disease, p. 214 (1993).
Chapron et al, "Gastric Retention of Enteric-Coated Magnesium Chloride Tablets" Abstract, Annals of Pharmacotherapy, 28(7-8):874-877 (1994).
Digenis et al, "Cross-Linking of Gelatin Capsules and Its Relevance to Their In Vitro-In Vivo Performance", Abstract, J. of Pharmaceutical Sciences, 83(7):915-921 (1994).
Vantini et al, In Vitro Study of a New Pancreatic Enzyme with High Lipase Content in Enteric Coated Microtablets, Abstract, Clinica Terapeutica, 142(5):445-451 (1993).
Yoshitomi et al, "Evaluation of Enteric Coated Tablet Sensitive to Pancreatic Lipase", Abstract, Chemical and Pharmaceutical Bulletin, 40(7):1902-1905 (1992).
Thoma et al, "The Solubility Kinetics of Enteric-Resistant Tablets Using Riboflavin Test Tablets. 6. Pharmaceutic-Technologic and Analytic Studies on Gastric Juice-Resistant Dosage Forms", Abstract, Pharmazie, 46(5):331-336 (1991).
Morishita et al, "Controlled Release Microspheres Based on Eudragit L100 for the Oral Administration of Erythromycin", Abstract, Drug Design and Delivery, 7(4):309-319 (1991).
Lin et al, "Tablet Formulation Study of Spray-dried Sodium Diclofenac Enteric-Coated Microcapsules", Abstract, Pharmaceutical Research, 8(7):919-924 (1991).
Hardy et al, "Evaluation of an Enteric and Therapeutics", Abstract, Alimentary Pharmacology and Therapeutics, 5(1):69-75 (1991).
Fasano et al, Mechanism of Action of Zonula Occludens (ZOT) Elaborated by Vibrio cholerae, Abstract (B-13), p. 31, 94th ASM General Meeting (May 23-27, 1994).
Fasano et al, Regulation of Intestinal Tight Junctions By Zonula Occludens Toxin (ZOT) Elaborated by Vibrio cholerae, Abstract, Clinical Research, 42(2):286A (1994).
Fasano et al, Mechanism of Action of Zonula Occludens Toxin (ZOT) Elaborated by Vibrio cholerae, Abstract (1060), Pediatrica Research, 35 (4/2):179A (1994).
Fasano et al, Mechanism of Action of Zonula Occludens Toxin (ZOT) Elaborated by Vibrio Cholerae, Abstract, Gastroenterology, 106(4):A232 (1994).
Kasper et al, "Cholera", Clinical Microbiology Reviews, 8(1):48-86 (1995).
Levine, "Current Status of Vaccine Development for Enteric Diseases", Seminars in Pediatric Infectious Diseases, 5(3):243-250 (1994).
Guandalini et al "Gli Enterovaccini" Febbre Enterica, pp. 109-121.
Guandalini et al, "Acute Infectious Diarrhoea", Management of Digestive and Liver Disorders In Infants and Children, pp. 319-349 (1993).
Fasano et al, Vibrio cholerae Produces a Second Enterotoxin, Which Affects Intestinal Tight Junctions, Proc. Natl. Acad. Sci. USA, 88:5242-5246 (1991).
Baudry et al, "Cloning of a Gene (zot) Encoding a New Toxin Produced by Vibrio cholerae", Infection and Immunity, 60(2):428-434 (1992).
Leong et al, "Identification of the Integrin-Binding Domain of the Yersinia pseudotuberculosis Invasin Protein", The EMBO Journal, 9(6):1979-1989 (1990).
De Magistris Teresa
Fasano Alessio
Rappuoli Rino
Uzzau Sergio
Chiron S.p.A.
Gupta Anish
Tsang Cecilia J.
University of Maryland at Baltimore
LandOfFree
Dosage composition for nasal delivery and method of use of the s does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dosage composition for nasal delivery and method of use of the s, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dosage composition for nasal delivery and method of use of the s will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-954947